Serum biomarker panel for the diagnosis of rheumatoid arthritis

Mun, Sora; Lee, Jiyeong; Park, Soo‐Jin; Shin, Jieun; Lim, Myung-Jae; Kang, Hee-Gyoo

doi:10.1186/s13075-020-02405-7

Cited by 43 publications

(28 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…An experimental study used label-free quantitative proteomics to characterize proteins with diagnostic potential, especially for seronegative RA patients. It has been demonstrated that serum amyloid A-4 protein (SAA4), retinol-binding protein-4 (RBP4), angiotensinogen (AGT) and vitamin D-binding protein (VDBP) are accurate enough to be used as diagnostic tools [ 115 ]. Glycoprotein YKL-40 can be used as a diagnostic biomarker because of its promising results [ 116 ].…”

Section: Clinical Aspects Of Ramentioning

confidence: 99%

Management of Rheumatoid Arthritis: An Overview

Radu

Bungău

2021

Cells

404

270

View full text Add to dashboard Cite

Rheumatoid arthritis (RA) is a multifactorial autoimmune disease of unknown etiology, primarily affecting the joints, then extra-articular manifestations can occur. Due to its complexity, which is based on an incompletely elucidated pathophysiological mechanism, good RA management requires a multidisciplinary approach. The clinical status of RA patients has improved in recent years due to medical advances in diagnosis and treatment, that have made it possible to reduce disease activity and prevent systemic complications. The most promising results were obtained by developing disease-modifying anti-rheumatic drugs (DMARDs), the class to which conventional synthetic, biologic, and targeted synthetic drugs belong. Furthermore, ongoing drug development has led to obtaining molecules with improved efficacy and safety profiles, but further research is needed until RA turns into a curable pathology. In the present work, we offer a comprehensive perspective on the management of RA, by centralizing the existing data provided by significant literature, emphasizing the importance of an early and accurate diagnosis associated with optimal personalized treatment in order to achieve better outcomes for RA patients. In addition, this study suggests future research perspectives in the treatment of RA that could lead to higher efficacy and safety profiles and lower financial costs.

show abstract

Section: Clinical Aspects Of Ramentioning

confidence: 99%

Management of Rheumatoid Arthritis: An Overview

Radu

Bungău

2021

Cells

404

270

View full text Add to dashboard Cite

show abstract

“…Prior research has shown that rheumatoid factor serves as an important index of diagnosis for rheumatoid diseases, with sensitivity and specificity being 60–90% and 85%, respectively. This finding indicates that the diagnosis of some patients with joint pain might not be accurate, especially at the early stages ( Mun et al, 2021 ). Our in-depth review of OA cases found the proportion of such patients was still on the increase ( Mobasheri, 2012 ).…”

Section: Discussionmentioning

confidence: 96%

A Novel Autophagy-Related Marker for Improved Differential Diagnosis of Rheumatoid Arthritis and Osteoarthritis

Huang¹,

Zheng

Liu

et al. 2021

Front. Genet.

View full text Add to dashboard Cite

Rheumatoid arthritis (RA) and osteoarthritis (OA) are two most common rheumatic diseases in the world. Although there are standard methods for the diagnosis of both RA and OA, the differentials in some cases are poor. With deepening research, the role of autophagy in maintaining cell homeostasis and thus enabling cells adapt to external environments has become increasingly prominent. Both RA and OA, two diseases with inherent differences in pathogenesis, gradually show differences in autophagy levels. Our study therefore aims to further understand differences in pathogenesis of RA and OA through in-depth studies of autophagy in RA and OA. We also define appropriate autophagy-related markers as recognition indicators. Differences in autophagy levels between RA and OA were found based on analysis of the Kyoto Encyclopedia of Genes and Genomes (KEGG) and single-sample gene set enrichment (ssGSEA). These differences were mainly caused by 134 differentially expressed genes (DEGs). In two autophagy-related genes, CXCR4 and SERPINA1, there existed significant statistical difference between RA and OA. An autophagy related index (ARI) was thus successfully constructed based on CXCR4 and SERPINA by binary logistic regression of the generalized linear regression (GLR) algorithm. Pearson analysis indicated that the expression of CXCR4, SERPINA1, and ARI were closely correlated with autophagy scores and immune infiltration. Moreover, ARI showed high disease identification through receiver operating characteristic (ROC) analysis (AUCtesting cohort = 0.956, AUCtraining cohort = 0.867). These results were then verified in GSE12021 independent cohort. In conclusion, ARI associated with autophagy and immune infiltration was successfully constructed for accurately identifying OA and RA. The index, thus, has great potential in clinical applications.

show abstract

“…Several proteins and peptides have been identified that are unique to serum proteome of RA patients [ 18 , 20 ]. A recent study compared the serum proteome profiles of seronegative patients with healthy controls [ 21 ]. However, to our knowledge, no study has compared the serum proteome profiles of all the RA serotypes based on ACPAs and RF.…”

Section: Introductionmentioning

confidence: 99%

LC-MS/MS-Based Serum Protein Profiling for Identification of Candidate Biomarkers in Pakistani Rheumatoid Arthritis Patients

Jahangir

John

Bhatti

et al. 2022

Life

View full text Add to dashboard Cite

Rheumatoid arthritis is an autoimmune disorder of complex disease etiology. Currently available serological diagnostic markers lack in terms of sensitivity and specificity and thus additional biomarkers are warranted for early disease diagnosis and management. We aimed to screen and compare serum proteome profiles of rheumatoid arthritis serotypes with healthy controls in the Pakistani population for identification of potential disease biomarkers. Serum samples from rheumatoid arthritis patients and healthy controls were enriched for low abundance proteins using ProteoMinerTM columns. Rheumatoid arthritis patients were assigned to one of the four serotypes based on anti-citrullinated peptide antibodies and rheumatoid factor. Serum protein profiles were analyzed via liquid chromatography-tandem mass spectrometry. The changes in the protein abundances were determined using label-free quantification software ProgenesisQITM followed by pathway analysis. Findings were validated in an independent cohort of patients and healthy controls using an enzyme-linked immunosorbent assay. A total of 213 proteins were identified. Comparative analysis of all groups (false discovery rate < 0.05, >2-fold change, and identified with ≥2 unique peptides) identified ten proteins that were differentially expressed between rheumatoid arthritis serotypes and healthy controls including pregnancy zone protein, selenoprotein P, C4b-binding protein beta chain, apolipoprotein M, N-acetylmuramoyl-L-alanine amidase, catalytic chain, oncoprotein-induced transcript 3 protein, Carboxypeptidase N subunit 2, Apolipoprotein C-I and Apolipoprotein C-III. Pathway analysis predicted inhibition of liver X receptor/retinoid X receptor activation pathway and production of nitric oxide and reactive oxygen species pathway in macrophages in all serotypes. A catalogue of potential serum biomarkers for rheumatoid arthritis were identified. These biomarkers can be further evaluated in larger cohorts from different populations for their diagnostic and prognostic potential.

show abstract

Serum biomarker panel for the diagnosis of rheumatoid arthritis

Cited by 43 publications

References 35 publications

Management of Rheumatoid Arthritis: An Overview

Management of Rheumatoid Arthritis: An Overview

A Novel Autophagy-Related Marker for Improved Differential Diagnosis of Rheumatoid Arthritis and Osteoarthritis

LC-MS/MS-Based Serum Protein Profiling for Identification of Candidate Biomarkers in Pakistani Rheumatoid Arthritis Patients

Contact Info

Product

Resources

About